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Although inherited fibrinogen disorders (IFD) are primarily considered to be bleeding disorders, they 
are associated with a higher thrombotic complication risk than defects in other clotting factors. 
Managing IFD patients with thrombosis is challenging as anticoagulant treatment may exacerbate 
the underlying bleeding risk which can be life-threatening. Due to the low prevalence of IFD, there is 
little information on pathophysiology or optimal treatment of thrombosis in these patients. We 
searched the literature for cases of thrombosis among IFD patients, and identified a total of 128 
patient reports. In approximately half of the cases, thromboses were spontaneous, while in the 
others trauma, surgery, and parturition contributed to the risk. The true mechanism(s) of thrombosis 
in IFD patients remain to be elucidated. A variety of anticoagulant treatments have been used in the 
treatment or prevention of thrombosis, sometimes with concurrent fibrinogen replacement therapy. 
There is no definite evidence that fibrinogen supplementation increases the risk of thrombosis, and 
it may potentially be effective in the treatment and prevention of both thrombosis and hemorrhage 
in IFD patients. 
Introduction 
Fibrinogen plays a key role in the process of coagulation. It functions not only as the precursor of the 
fibrin net that gives structure to blood clots, but also as a promoter of platelet aggregation and 
fibrinolysis. Two types of inherited fibrinogen disorder (IFD) are recognized, both of which are rare: 
Type I involves reduced quantities of fibrinogen, whilst type II involves qualitative abnormality. Type 
I IFD includes afibrinogenemia (absence of fibrinogen, plasma level < 0.1 g/l) and 
hypofibrinogenemia (low plasma levels of fibrinogen, 0.1 ?--1.5 g/l), while type II encompasses 
dysfibrinogenemia (normal fibrinogen levels (1.5 ?--3.5 g/l) with low functional activity) [1, 2]. A small 
number of patients have both hypofibrinogenemia and dysfibrinogenemia, and this condition is 
described as hypodysfibrinogenemia. IFD is considered as rare on the basis that afibrinogenemia and 
dysfibrinogenemia each have an estimated prevalence of one in 1,000,000 [1--3], although the 
frequency of hypofibrinogenemia is believed to be higher [1].  
Increased bleeding is generally considered as the primary manifestation of IFD, with umbilical cord 
bleeding affecting as many as 85% of neonates with afibrinogenemia [4]. Patients with 
hypofibrinogenemia and dysfibrinogenemia have a lower risk of bleeding events, but these 
individuals are still at higher risk than the general population, for example during surgery or 
pregnancy [5]. 
Despite the deficiency of fibrinogen, there is a potential risk of thromboembolic complications 
among IFD patients [6, 7]. Managing IFD patients with thrombosis is challenging as they may be at 
risk of life-threatening hemorrhage [8], or require hemostatic support following surgery, trauma, or 
childbirth [9, 10]. In such situations, clinicians face the difficult task of providing sufficient 
hemostasis while minimizing the risk of thromboembolism. Due to the low prevalence of IFD, there 
is little information on pathophysiology or optimal treatment of thrombosis in these patients.  
Literature Review 
In order to obtain more information about thrombosis in IFD patients, we searched the PubMed 
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yielded a total of 490 results. Based on titles and abstracts, we identified 86 potentially relevant 
publications. Further full-text examination of these publications identified 62 case reports of 
patients with IFD experiencing thrombotic symptoms. We also identified 8 clinical studies or case 
series (>3 patients) that included reports of thrombosis among IFD patients. However, these 
publications provide minimal information on the individual patients concerned or the circumstances 
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any additional details.  
The case reports are summarised summarized in supplemental table 1 (available at 
http://content.karger.com/ProdukteDB/produkte.asp?doi=452864): 72 patients with thrombotic 
events were described in the 62 publications. A summary of data from the clinical studies and case 
series is presented in table 1. A total of 56 patients experiencing at least one thrombotic episode are 
described. Consequently, the total number of IFD patients with thrombosis is 128. Twenty-five25 
patients were diagnosed with afibrinogenemia, 79 with dysfibrinogenemia, 16 with 
hypofibrinogenemia, and six 6 with hypodysfibrinogenemia. Venous thrombosis appears to be the 
most common thrombotic event, having been reported in 74 patients (58%). In 35 of these cases 
(27% of the overall population), pulmonary embolism was the manifestation. Arterial thrombosis 
was reported in 31 patients (24%). In a small number of patients (n = 5), combinations of venous and 
arterial events occurred at the same time. There were also a number of reports of ischemia and 
necrosis where it could not be clearly established whether the cause was venous or arterial 
thrombosis. Thromboses occurred in a variety of different locations, including the legs, vena cava, 
portal system, and pulmonary artery. 
In a large European case series of patients with dysfibrinogenemia (n = 101), the age- and sex-
adjusted risk of thrombotic events after diagnosis of dysfibrinogenemia was 18.7/1,000 patient- 
years [7]. The overall risk of thrombotic events did not differ between men and women, and the 
cumulative incidence of thrombotic events at the age of 50 years was estimated to be 30.1% (95% 
confidence interval, 20.1% to --43.5%). A large study of Chinese cases included retrospective analysis 
of clinical manifestations among 102 individuals with dysfibrinogenemia; thrombosis was reported in 
four 4 of these patients (3.9%) [11]. 
Risk Factors for Thrombosis 
In 22 of the 72 case reports (31%), thrombosis developed after a surgical procedure, parturition, or 
trauma. This suggests that, as in the general population, such events can precipitate thrombosis 
among individuals with IFD, including those without previous history of thrombosis. Epidemiological 
risk factors for thrombosis include smoking, hypertension, obesity, and the use of oral 
contraceptives [12--14]. Such risk factors were present in 9nine of the cases that we identified (13%), 
with some patients having more than one risk factor. Furthermore, in four 4 cases (6%) factor V 
Leiden mutation was present as a thrombophilic risk. Despite these observations, approximately half 
of thromboses appear to have occurred in the absence of surgery/trauma or epidemiological risk 
factors, meaning that IFD itself was the probable cause. 
In the large European case series of dysfibrinogenemia patients, the authors examined whether 
there was a relationship between plasma fibrinogen levels and thrombotic risk [7]. No such 
relationship was found, with respect to either fibrinogen activity or fibrinogen activity:-antigen ratio 
where available.  
One question of interest is whether fibrinogen substitution constitutes a risk factor for 
thromboembolism in IFD patients. Of the patients presented in table 1, 44% (32 out of 72) had 
previously received fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or 
fibrinogen concentrate before thrombosis. However, there are reports of a number of patients who 
had been receiving fibrinogen for many years without experiencing any thrombotic symptoms [15--
17] while others showed a different course. Some experienced onset of thrombotic symptoms after 
more than a year of being off fibrinogen [17] or experienced thrombosis before as well as after 
receiving fibrinogen [18]. A close temporal relationship between the administration of fibrinogen 
concentrate and the development of thrombotic events was observed mainly in cases where 
fibrinogen was administered as perioperative hemostatic management [9, 19, 20]. In one of these 
cases, the patient had also had a thrombotic stroke prior to surgery and fibrinogen infusion [20]. 
Thrombotic events also developed postoperatively when cryoprecipitate was used to maintain 
fibrinogen levels [10, 21]. Given the small number of cases and the broad range of clinical 
circumstances, it is not possible to conclude from the case reports that any form of fibrinogen 
replacement increases the risk of thrombotic events.  
Pathophysiology of Thrombosis in Inherited Fibrinogen Disorders 
IFD, particularly certain forms of dysfibrinogenemia, is associated with increased risk of thrombosis 
[5]. Such a relationship may appear counterintuitive, considering that fibrinogen serves as a primary 
substrate of coagulation. One hypothesis for the increased thrombotic risk is that concentrations of 
circulating thrombin are increased in fibrinogen deficiency [22, 23]. In the past, fibrin has been 
described as antithrombin I due to its ability to bind thrombin [24]. Thrombin is sequestered by the 
fibrin clot as it forms, reducing the amount of free thrombin in the circulation [23]. This in vivo 
clearance mechanism does not occur in patients with afibrinogenemia. Free thrombin remaining 
unbound to fibrin is not contained locally [25] , and its potential effects include platelet activation 
[23]. It has also been shown that fibrin can down-regulate thrombin generation [22]. Therefore, a 
reduction or absence of functional fibrinogen could directly increase thrombin activity. 
Soluble fibrinogen competitively inhibits normal platelet adhesion to immobilized fibrinogen [26]. 
Accordingly, experiments suggest that adhesion of normal platelets suspended in afibrinogenemic 
plasma to immobilized fibrinogen is high, and that this can be reversed by soluble fibrinogen [26]. 
The addition of von Willebrand factor (vWF) to afibrinogenemic platelet-rich plasma supports 
platelet aggregation induced by adenosine diphosphate (ADP) [27]. This suggests that vWF may 
potentially play a compensatory role in the absence of fibrinogen.  
Thrombus formation has been shown to occur in mice lacking fibrinogen and vWF. The thrombi that 
formed in this model were unstable and, as a consequence, detached from the subendothelium of 
the arterioles where they formed [28]. Translocation and embolization of the thrombi led to 
downstream occlusion of blood vessels.  
The mechanisms above suggest that the absence of fibrinogen may lead to increased levels of other 
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aimed at normalizing fibrinogen levels may, potentially, reverse the compensatory adjustments and 
reduce prothrombotic tendency.  
In patients with dysfibrinogenemia, thrombosis may be caused by pre-existing risk factors such as 
antiphospholipid antibody syndrome, or by certain mutations in the fibrinogen gene. For example, in 
Dusart syndrome the mutation A-ɲ ? ? ?ĂƌŐŝŶŝŶĞA?A?ĐǇƐƚĞŝŶĞŝŶĐƌĞĂƐĞƐƚŚĞďƌŝƚƚůĞŶĞƐƐŽĨďůŽŽĚĐůŽƚƐ
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thrombin from binding to fibrin, leading to an increase in the level of free thrombin in the blood 
[11]. A variety of alterations in the strength, structure, or stability of the fibrin clot may potentially 
lead to the occurrence of thrombosis [7, 30]. 
Overall, despite the identification of several factors which may contribute to thrombosis in patients 
with IFD, the exact mechanism(s) behind each clinical occ
Prevention of Thrombosis 
The key to optimal management of patients with IFD is to achieve an appropriate balance between 
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presentation. This should enable effective prevention of thrombosis while also maintaining a low risk 
of hemorrhage. The literature suggests that thromboembolic events are not always preventable, but 
it should be possible to minimize their occurrence and successfully treat the few cases that still 
occur. IFD patients with underlying thrombotic risk(s) may potentially be susceptible to thrombotic 
complications when hemostasis is normalized by replacement therapy. 
A number of therapeutic options have been explored for the prevention of thrombosis in patients 
with IFD. The principal options are briefly reviewed below. 
Anticoagulant Therapy 
Administration of low-molecular-weight heparin (LMWH, enoxaparin) has been advocated in 
advance of surgery for IFD patients with a thrombotic phenotype [1, 31]. In afibrinogenemia, LMWH 
(15,000 anti-factor Xa activity units twice- daily) has been used to prevent thromboembolism [32]. 
LMWH thromboprophylaxis has also been pursued in dysfibrinogenemia [33]. Some authors have 
suggested administering small doses of heparin alongside fibrinogen therapy [1, 2].  
Other anticoagulant drugs have also been used, including vitamin K antagonists, factor Xa inhibitors, 
and aspirin. Supplemental table 1 (available at 
http://content.karger.com/ProdukteDB/produkte.asp?doi=452864) provides an indication of the 
extent to which these treatments have been used in patients experiencing thrombosis.  
Fibrinogen Replacement Therapy 
Fibrinogen replacement therapy is often employed for the treatment or prevention of bleeding in 
patients with IFD. Despite the focus on bleeding, fibrinogen replacement therapy can also affect the 
risk of thrombosis. It has previously been suggested that increased risk of thrombotic complications 
may be an inherent risk of fibrinogen replacement therapy [34]. Thus, a degree of caution is 
warranted when treating IFD patients with fibrinogen. However, as described above, it is possible 
that such treatment may reverse procoagulant mechanisms that compensate for fibrinogen 
deficiency, thereby reducing the pre-existing risk of thrombosis in IFD patients. This perspective was 
reflected in the conclusions of a recent review of thromboembolism in afibrinogenemia: frequent, 
low-ĚŽƐĞĨŝďƌŝŶŽŐĞŶƌĞƉůĂĐĞŵĞŶƚǁĂƐƐƵŐŐĞƐƚĞĚƚŽďĞĂ ?ƐĂĨĞĂŶĚĞĨĨĞĐƚŝǀĞ ?ƚƌĞĂƚŵĞŶƚ ? ? ? ? ?dŚĞ
options for fibrinogen supplementation include fibrinogen concentrate, cryoprecipitate, and fresh 
frozen plasma. Fibrinogen concentrate may reduce the risk of thrombosis in IFD patients compared 
with cryoprecipitate because, unlike cryoprecipitate and plasma, it does not contain coagulation 
factors other than fibrinogen (e.g. factor VIII, von Willebrand factorvWF) [5, 32, 36]. In 
afibrinogenemia with elevated prothrombin activation, fibrinogen concentrate has been shown to 
reduce the level of prothrombin activation [37]. Compared with therapeutic plasma, cryoprecipitate 
and fibrinogen concentrate may be considered as preferable because of reduced infusion volumes 
[5]. 
For severe bleeding or major surgery, a target plasma fibrinogen level of >1.0 g/l is recommended, 
which may be achieved with a fibrinogen dose of 50 ?--100 mg/kg followed by smaller doses every 2 ?
--4 days [1, 33]. Long periods without symptoms are common [1] and,; as a result, it is common for 
IFD patients to receive fibrinogen replacement therapy only in response to bleeding episodes. 
However, for patients with a personal or family history of severe bleeding, long-term prophylaxis 
may be considered. In this context, administration of fibrinogen is recommended every 7-- ?14 days, 
with dose adjustment to maintain the plasma fibrinogen concentration above 0.5 g/l [1, 4, 33]. In 
pregnant women with IFD and a history of adverse pregnancy outcomes, fibrinogen 
supplementation twice per week throughout pregnancy should be considered [4, 33]. Treatment to 
achieve a higher plasma fibrinogen level (ideally >2.0 g/l) is recommended during labor [4]. 
Treatment of Thrombosis 
Supplemental table 1 (available at 
http://content.karger.com/ProdukteDB/produkte.asp?doi=452864) shows that a broad array 
pharmacotherapeutic options that have has been used for the treatment of thrombosis in IFD 
patients. Reported therapies include anticoagulant, antiplatelet or vasodilatory drugs such as 
LMWH, rivaroxaban, warfarin, aspirin, clopidogrel, urokinase, phenprocoumon, streptokinase, 
pentoxifylline, nifedipine, and nafamostat [15, 16, 18, 38--44]. Concomitant fibrinogen replacement 
therapy may be administered to reduce the risk of severe hemorrhage [16, 17, 38]. The choice for of 
specific drugs and whether to initiate concomitant fibrinogen replacement will depend on the 
specific clinical situation and patient history. In the large case series of patients with 
dysfibrinogenemia, all patients with venous thromboembolism were treated with anticoagulant 
therapy for up to 1 year, and antiplatelet medication was given to patients with arterial events [7]. 
In some instances, pharmacological interventions alone may not be sufficient. Surgical interventions, 
including thrombus removal, resection and inferior vena cava filter placement, may be considered. 
Favorable outcomes have been reported with both pharmacotherapy and surgery in the majority of 
patients [19, 41, 42]. In seven 7 cases (10%), the thrombotic event was fatal, while the rest made a 
full recovery. 
Conclusion 
Although thrombosis in IFD patients is uncommon, it is well reported in the literature. Known risk 
factors such as surgery, trauma, and parturition increase the likelihood of thrombosis, whilst in 
approximately half of the cases the thrombotic event was spontaneous. The true mechanism(s) of 
thrombosis in IFD patients remain to be elucidated. Although it has been suggested that fibrinogen 
treatment may be a risk factor for thrombosis, the published data do not support this notion. 
Compensatory regulation of other clotting factors among IFD patients may be reversed by fibrinogen 
replacement therapy, potentially decreasing the risk of thrombosis. Managing thrombosis in IFD 
patients is challenging because of the need to balance the need for anticoagulation with the risk of 
hemorrhage. Fibrinogen supplementation may be effective for the treatment and prevention of both 
thrombosis and hemorrhage in IFD patients.  
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